Nonpharmacological Interventions for Depressive Symptoms in End-Stage Renal Disease: A Systematic Review

2019 ◽  
Vol 42 (6) ◽  
pp. 462-473
Author(s):  
Xin Wen ◽  
Yu Wang ◽  
Qiuge Zhao ◽  
Hongrui Zhang ◽  
Huage Shi ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Large Scale ◽  
Psychological Intervention ◽  
Cochrane Library ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Cochrane Library

Depressive symptoms are common in patients with end-stage renal disease, which can affect treatment and prognosis. We aimed to evaluate the effects of nonpharmacological interventions for depressive symptoms in end-stage renal disease. Eligible studies were identified using PubMed, Web of Science, the Cochrane Library, Embase, and PsycNET (up to March 2019). We identified 24 studies including 1,376 patients. We found that psychological intervention (−0.60, 95% confidence interval [CI] = [–0.87, –0.33]), exercise (−1.13, 95% CI = [–1.56, –0.69]), and manual acupressure (−0.26, 95% CI = [–0.50, 0.03]) were associated with a significant effect on depressive symptoms. However, few studies reported adverse events, and conclusions about safety should be drawn cautiously. While the available data show that nonpharmacological interventions are potential strategies to alleviate depressive symptoms of patients with end-stage renal disease, recommendation of the most efficacious interventions for this population will require future randomized controlled trials with large-scale, long-term intervention.

scholarly journals A Review of the Potential Benefits of Pentoxifylline in Diabetic and Non-Diabetic Proteinuria

2011 ◽  
Vol 14 (1) ◽  
pp. 128 ◽  
Author(s):  
Shirinsadat Badri ◽  
Simin Dashti-Khavidaki ◽  
Mahboob Lessan-Pezeshki ◽  
Mohammad Abdollahi
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Large Scale ◽  
Kidney Diseases ◽  
Scientific Basis ◽  
Sustained Reduction ◽  
Number Of Patients ◽  
Stage Renal Disease ◽  
End Stage

Chronic kidney disease (CKD) as a considerable health problem may have proteinuria as the main complication and strong risk factor to reach end-stage renal disease (ESRD). Decreasing proteinuria is the mainstay of therapy in order to delay the progression of CKD. Current therapeutic regimens provide only partial renoprotection, and a substantial number of patients who have proteinuria progress to ESRD. Pentoxifylline (PTF) is known for its potent inhibitory effects against cell proliferation and inflammation which play important roles in CKD progression. Data derived from both human studies and animal models demonstrated that PTF has broad-spectrum renoprotective effects and therefore, provide a scientific basis for the use of PTF as an anti-proteinuric agent. Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF. Whether the long-term use of PTF could be a pharmacological alternative for delaying or preventing the development of end stage renal disease, is among the questions that remained to be appropriately answered in large-scale clinical trials.

Frequency of Gastrointestinal Diseases in Patients with End-Stage Renal Disease Treated with Long Term Dialysis

2018 ◽  
Vol 2 (2) ◽  
pp. 105-112
Author(s):  
Lutfi Zylbeari ◽  
Zamira Bexheti ◽  
Gazmend Zylbeari ◽  
Ferizate Haxhirexha ◽  
Kastriot Haxhirexha
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Gastrointestinal Diseases ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 18 (7) ◽  
pp. 3471
Author(s):  
Hyeon-Ju Lee ◽  
Youn-Jung Son
Keyword(s):  
Systematic Review ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Associated Factors ◽  
Meta Analysis ◽  
Screening Tools ◽  
Cochrane Library ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Hemodialysis is the most common type of treatment for end-stage renal disease (ESRD). Frailty is associated with poor outcomes such as higher mortality. ESRD patients have a higher prevalence of frailty. This systematic review and meta-analysis aimed to identify the prevalence and associated factors of frailty and examine whether it is a predictor of mortality among ESRD patients undergoing hemodialysis. Five electronic databases including PubMed, Embase, CINAHL, Web of Science, and Cochrane Library were searched for relevant studies up to 30 November 2020. A total of 752 articles were found, and seven studies with 2604 participants in total were included in the final analysis. The pooled prevalence of frailty in patients with ESRD undergoing hemodialysis was 46% (95% Confidence interval (CI) 34.2−58.3%). Advanced age, female sex, and the presence of diabetes mellitus increased the risk of frailty in ESRD patients undergoing hemodialysis. Our main finding showed that patients with frailty had a greater risk of all-cause mortality compared with those without (hazard ratio (HR): 2.02, 95% CI: 1.65−2.48). To improve ESRD patient outcomes, healthcare professionals need to assess the frailty of older ESRD patients, particularly by considering gender and comorbidities. Comprehensive frailty screening tools for ESRD patients on hemodialysis need to be developed.

Long-term hemodialysis therapy in neonates and infants with end-stage renal disease: a 16-year experience and outcome

2015 ◽  
Vol 31 (2) ◽  
pp. 305-313 ◽  
Author(s):  
Shirley Pollack ◽  
Israel Eisenstein ◽  
Mahdi Tarabeih ◽  
Hadas Shasha-Lavski ◽  
Daniella Magen ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Neonates And Infants

scholarly journals SP347MORTALITY AND BONE SAFETY OUTCOMES IN PATIENTS WITH END-STAGE RENAL DISEASE RECEIVING LANTHANUM CARBONATE: A LONG-TERM, OBSERVATIONAL STUDY

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii226-iii227
Author(s):  
Alastair Hutchison ◽  
Ravi Thadhani ◽  
Gillian Hall ◽  
Andrew Whelton ◽  
Heinrich Achenbach ◽  
...  
Keyword(s):  
Observational Study ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Lanthanum Carbonate ◽  
Safety Outcomes ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document